Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0XDAFK
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
LT4212552T ADC13
|
|||||
| Synonyms |
ADC13
Click to Show/Hide
|
|||||
| Organization |
Daiichi Sankyo Company Limited
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
6.9
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
LT4212552T ADC13 payload
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase I (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-Gly-Gly-Phe-Gly
|
Linker Info | ||||
| Conjugate Type |
Cysteine-maleimide conjugation
|
|||||